----
Current ValuationThe current P/E ratio is 37.69, above the reasonable range, cheaper than 9.46% of the time in the past 3 years, and the industry ranks 27/52, the industry Median 6.62.
37.69xP/E
HK$5.55Stock price
HK$0.15Earnings per share
37.69xP/E
Stock priceHK$5.55Earnings per shareHK$0.15
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- 25.04x
- Typical range
- 16.89x–34.96x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 6.62x
013263952
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 6.62x
0x20x40x60x80x100x
| Name/Symbol | |||
|---|---|---|---|
01276HKHENGRUI PHARMA | 36.10x | 20.95% | HK$321.11B |
01177HKSBP GROUP | 37.69x | 110.61% | HK$103.69B |
06996HKANTENGENE-B | 37.74x | 246.23% | HK$2.33B |
03737HKZHONGZHIPHARM | 32.35x | -- | HK$656.34M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
